The binding of Bcl-2 to Beclin-1 reduces Beclin-1's capacity to induce autophagy. Here, we have tested whether the interaction is reciprocated by loss of Bcl-2's anti-apoptotic function. We targeted Bcl-2 to mitochondria or endoplasmic reticulum (ER) and induced apoptosis using several apoptotic stimuli that initiate ER and/or mitochondrial signaling pathways (UV radiation, TNF and cycloheximide, staurosporine, thapsigargin and tunicamycin). When Beclin-1 and Bcl-2 were expressed together in HeLa cells, Beclin-1 (but not Beclin-1 lacking the Bcl-2-binding domain) followed Bcl-2 to the appropriate organelle with complete or near-complete overlap (comprising 60 and 30% of cells, respectively). The interaction between Beclin-1 and Bcl-2 was verified by immunoprecipitation, and a membrane-proximate localization of Beclin-1 was shown by immunoelectron microscopy. Apoptosis was followed by measuring changes in nuclear morphology, caspase-3 activity, poly-ADP-ribose polymerase cleavage or punctation of mRFP-Bax on mitochondria. Binding of Beclin-1 to Bcl-2 did not modify apoptosis irrespective of Bcl-2 concentration, location or apoptotic stimulus. A similar result was obtained in Atg5À/À cells that are autophagy-deficient, arguing against compensation for the loss of protection by Bcl-2 by autophagy-mediated survival induced by Beclin-1. Hence, although Beclin-1 contains a BH3-only motif typical of pro-apoptotic proteins, it is a negligible modulator of Bcl-2's anti-apoptotic function.
Introduction
Autophagy is a cellular process in which portions of cytoplasm and intracellular organelles are sequestered within double-membrane vesicles, the autophagosomes, before delivery to lysosomes for degradation (Klionsky, 2007; Mizushima et al., 2008) . It has been proposed that autophagy has both life and death functions. Classically, autophagy promotes cell survival under nutrient-limited conditions by supplying cells with substrates for ATP production and protein synthesis through self-digestion of cytoplasmic components (Meijer and Codogno, 2004) . Autophagy also functions beyond simple energy provision, as without 'basal' autophagy achieved by targeted deletion of the autophagy genes ATG5 or ATG7 in neurons, neurons develop toxic poly-ubiquitylated inclusions, leading to cell toxicity and death (Hara et al., 2006; Komatsu et al., 2006) . The role of autophagy in cell death is less well understood. In cancer cells, autophagy inhibited starvation-induced apoptotic death (Boya et al., 2005) and also necrotic cell death, especially in conjunction with a block in apoptosis (Jin and White, 2007; Karantza-Wadsworth et al., 2007) . Conversely, autophagy was required for necrotic death of neuronal cells in C. elegans (Samara et al., 2008) , for stress-mediated necrosis in apoptosis-deficient BaxÀ/ÀBakÀ/À mouse embryonic fibroblasts (MEFs) (Shimizu et al., 2004; Ullman et al., 2008) and loss of autophagy through deletion of Atg7 rescued neurons from death after hypoxia/reperfusion (Koike et al., 2008) . Resolving the relationship between autophagy and apoptosis is especially complex, as both are induced by similar stimuli and impact on each other's functions (Maiuri et al., 2007c; Levine et al., 2008) .
Autophagy, like apoptosis, is a tightly regulated biological process that is genetically controlled (Mizushima et al., 2002 (Mizushima et al., , 2008 Yoshimori, 2004; Klionsky, 2007) . Amongst the autophagy genes, beclin-1/ATG6 is a key initiator of autophagy in mammalian cells Cao and Klionsky, 2007) , although it may be bypassed under certain conditions (Chu et al., 2007; Scarlatti et al., 2008) . Beclin-1 was first identified as a protein that interacts with the anti-apoptotic proteins Bcl-2 and Bcl-xL, but not with Bax/Bak (Liang et al., 1998) , and classified recently as a BH3-only protein (Oberstein et al., 2007; Maiuri et al., 2007b) . BH3-only proteins are pro-apoptotic regulators of apoptosis, the binding of which to anti-apoptotic Bcl-2 members is one mechanism of facilitating the activation of Bax/Bak, crucial mediators of the mitochondrial pathway of apoptosis (Scorrano and Korsmeyer, 2003; Certo et al., 2006; Adams and Cory, 2007) . Like other BH3-only proteins, the BH3 domain of Beclin-1 binds to anti-apoptotic Bcl-2 family proteins within their hydrophobic groove (Feng et al., 2007; Oberstein et al., 2007; Maiuri et al., 2007b; Ku et al., 2008; Sinha et al., 2008) . Thus, in reconstituted systems it is displaced from Bcl-2/-xL/-w by Bad, tBid or the BH3-mimetic compound, ABT737, though not by Bax/Bak (Erlich et al., 2007; Maiuri et al., 2007b) . It is important to note that the interaction between endogenous Beclin-1 and Bcl-2 was found to inhibit Beclin-1-dependent autophagy in yeast and mammalian cells . Whether Beclin-1 binding to Bcl-2-like proteins regulates the anti-apoptotic function of the latter during apoptosis induced under nutrient-replete conditions is not known.
The aim of the present experiments was to investigate whether Beclin-1 would disrupt the ability of Bcl-2 to protect against apoptotic insults. To investigate protection against a wide range of insults, we targeted Bcl-2 to mitochondria (mit) or endoplasmic reticulum (ER), as binding of Beclin-1 to ER-Bcl-2 or ER-Bcl-xL, but not to mit-Bcl-2 or mit-Bcl-xL, were reported to inhibit starvation-induced autophagy Maiuri et al., 2007b) . One might postulate, therefore, that an interaction between Beclin-1 and Bcl-2 in mitochondria will reveal a stronger Bcl-2-neutralising function. We show that overexpressed Beclin-1 interacts equally well with Bcl-2 variants that are exclusively targeted to the mitochondrial or ER membranes (mitBcl-2 and ER-Bcl-2). These interactions were observed in cells in which autophagy is active as well as in cells in which autophagy is totally deficient because of ATG5 gene deletion. We show that Beclin-1 does not induce or alter stimulus-induced apoptosis when expressed on its own, nor does it disrupt the anti-apoptotic function of Bcl-2, regardless of ER or mitochondrial localization in autophagy proficient or deficient cells. Our results suggest that Beclin-1 is at best a weak modulator of Bcl-2's anti-apoptotic function, and that suppression of tumorigenesis in mammals by Beclin-1 is not related to its capacity to bind to Bcl-2 through its BH3-only domain.
Results
Overexpressed Beclin-1 tracks the intracellular location of Bcl-2 To show Beclin-1 binding to Bcl-2, we examined first whether Beclin-1 colocalized with Bcl-2 irrespective of Bcl-2's organellar target. After 48 h expression of Beclin-1-GFP and the targeted Bcl-2 constructs (mit-Bcl-2 and ER-Bcl-2) or non-targeted wt-Bcl-2, cells were stained for Bcl-2 expression (Figure 1a) . Without overexpression of Bcl-2, ectopically expressed Beclin-1-GFP was distributed evenly throughout the cytoplasm, consistent with recent data examining the distribution of Beclin-1-GFP in a transgenic mouse model (Arsov et al., 2008) . However, upon cotransfection with the Bcl-2 variants, the pattern changed, being uniquely organellar with mit-or ER-Bcl-2 and intermediate between the two with wt-Bcl-2. To confirm that mit-Bcl-2 and ER-Bcl-2 were localized to mitochondria and ER, respectively, cells were stained with mitotracker orange (to label mitochondria) and anti-KDEL antibody (to label ER) (Figure 1b) . With mit-Bcl-2, Beclin-1-GFP was localized almost exclusively to mitotracker-positive structures, which clustered, as commonly observed when outer mitochondrial membrane proteins are overexpressed using the X-TMB target (Kaufmann et al., 2003) . This clustering did not obstruct the viability and growth of the cells (data not shown). With ER-Bcl-2, Beclin-1-GFP colocalized almost exclusively to KDEL-positive compartments, which showed a punctate pattern throughout the cytoplasm. With wt-Bcl-2, about 50% of Beclin-1-GFP distributed in the mitochondria, whereas the remainder either localized to the ER and to the nuclear membrane, or was more diffuse. Expression of human Flag-Beclin-1 lacking GFP gave similar patterns of codistribution with the Bcl-2 variants as those obtained with mouse Beclin-1-GFP (Supplementary Figure S1 ). Thus, the pattern shown in Figure 1 was not because of modification of Beclin-1 at the C-terminus.
To quantify the prevalence of the distinct colocalization patterns within the cellular population, Beclin-1-GFP-expressing cells were scored into three groups: group one showing a diffuse cytoplasmic pattern, group two showing partial compartmentalization and group three showing complete compartmentalization (Figure 1c ). This analysis revealed that Beclin-1-GFP was completely localized to mitochondria or ER in 60% of cells cotransfected with mit-Bcl-2 or ER-Bcl-2, and partially compartmentalized in 30% of the cells, altogether accounting for 90% of the total cells transfected. Cells coexpressing Beclin-1-GFP and wt-Bcl-2 showed partial compartmentalization in 80% of the cells, whereas those expressing no exogenous Bcl-2 showed no apparent preference.
To further confirm independent membrane localization of Beclin-1 at mitochondria and ER, we analysed the localization of Beclin-1-GFP after immunogold labeling against anti-GFP antibody by electron microscopy. In the presence of Beclin-1-GFP and mit-Bcl-2, the gold particles were mainly located at mitochondria (Figure 2 ; 31±3 grains per unit length on mitochondria vs 10±6 grains on ER; mean±range of 10-15 mitochondria and 2-3 ER structures, two cells); mitochondria were clustered as found by immunofluorescence. In cells transfected with Beclin-1-GFP and ER-Bcl-2, the majority of gold particles were localized at the ER (Figure 2 ; 43 ± 7 grains per unit length on ER vs 5±0.2 on mitochondria, mean±range, 5 ER structures and 8-10 mitochondria, two cells). For wt-Bcl-2, Beclin-1-GFP was present mainly at the nuclear envelope or at the mitochondrial membranes (Figure 2) . No specific membrane localization of Beclin-1-GFP was observed without overexpression of Bcl-2.
To confirm that mit-and ER-Bcl-2 do not bind to overlapping structures, we coexpressed mRFP-and GFP-tagged versions of mit-Bcl-2 and/or ER-Bcl-2.
When the same Bcl-2 variant was tagged with either mRFP or GFP and coexpressed, there was complete overlap in the colocalization, analysed by confocal microscopy (Supplementary Figure S2) . However, when mit-or ER-Bcl-2 with different tags in either combination was coexpressed, virtually no colocalization was detected. Together, these data show that Beclin-1 follows overexpressed Bcl-2 to whatever organelle the Bcl-2 is targeted to.
Beclin-1 forms a complex with Bcl-2 To show that Beclin-1 forms a complex with the differentially localized Bcl-2 variants, HeLa cells cotransfected with Flag-Beclin-1 and the different variants of Bcl-2 were lysed and Beclin-1 was immunoprecipitated using anti-Flag-conjugated sepharose beads (Figure 3 ). Equal amounts of each of the Bcl-2 variants were pulled down with Beclin-1, in keeping with the equivalent amounts of Beclin-1 and each Bcl-2 variant expressed (see Figure 3a) . By contrast, no wt-Bcl-2 was immunoprecipitated using Flag-Beclin-1(DBcl-2BD), which lacks the Bcl-2-binding domain (amino acids 80-150), indicating that the redistribution of Beclin-1 is because of its binding to Bcl-2 (Figure 3a) . Accordingly, Beclin-1(DBcl-2BD)-GFP also failed to colocalize with each of the Bcl-2 variants when investigated by immunocytochemistry (Figure 3c) . A similar amount of Bcl-2 was coeluted with Flag-Beclin-1 when a 3 Â Flag peptide was used to release Beclin-1 rather Figure 1 Beclin-1-GFP and Bcl-2 variants colocalize in cells. (a) HeLa cells on coverslips were transfected with Beclin-1-GFP (Bec-GFP) or cotransfected with Beclin-1-GFP and equal amounts of Bcl-2 variants (mit-Bcl-2, ER-Bcl-2 and wt-Bcl-2). Cells were fixed with 3% paraformaldehyde after 48 h, labeled with antibodies against Bcl-2, counterstained with Hoechst 33342 and imaged using confocal microscopy. In the merged images, yellow color indicates colocalization of Beclin-1-GFP with the Bcl-2 variants. Bar, 10 mm. (b) After 48 h, some cells were loaded with 100 nM mitotracker orange (MTO) for 15 min before fixation to visualize mitochondria, or stained with anti-KDEL after fixation to visualize the ER. Note lack of expression of Beclin-1-GFP at the ER in cells coexpressing mitBcl-2, and lack of expression of Beclin-1-GFP at the mitochondria in cells coexpressing ER-Bcl-2. (c) Quantified distribution of Beclin-1-GFP in HeLa cells expressing endogenous Bcl-2, or coexpression of wt-Bcl-2, mit-Bcl-2 or ER-Bcl-2. Cyto, cytoplasmic distribution; comp, compartmentalized distribution; cyto þ comp, mixed phenotype. At least 200 cells under each condition were analysed per experiment. Results are means ± s.d. of four independent experiments. Statistical significance was determined using ANOVA followed by Newman-Keuls analysis; ***Po0.001 for cytoplasmic distribution of Beclin-1-GFP; zzz Po0.001, z Po0.05 for compartmentalized distribution of Beclin-1-GFP; ### Po0.001 for cyto þ comp distribution of Beclin-1-GFP expressing Bcl-2 variants compared with cells expressing endogenous Bcl-2.
Bcl-2/Beclin-1 interactions and apoptosis IA Ciechomska et al than detergent, further showing that Bcl-2 was not bound to the beads non-specifically (data not shown). Moreover, Beclin-1 was completely depleted from the supernatant by the anti-Flag antibody (Figure 3b) , showing that all the Beclin-1 expressed can be accounted for. Thus, Beclin-1 forms a complex with Bcl-2 that can potentially modify Bcl-2's anti-apoptotic activity.
To show that the interaction between Bcl-2 and Beclin-1 is functional, we determined whether autophagy is reduced by their binding to Bcl-2 Maiuri et al., 2007b) by monitoring mRFP-LC3. Expression of the Bcl-2 variants reduced the amount of autophagy induced by Beclin-1 under nutrient-replete conditions in the presence of pepstatin A and E64d, inhibitors of lysosomal degradation (Figures 4a-c) . A twofold increase in the intensity of diffuse cytoplasmic coexpressed mRFP-LC3 was measured compared with cytoplasm in the punctate form observed in cells expressing Beclin-1 alone (example in Figure 4a , percentage of cells showing each phenotype quantified in Figure 4b ). Bcl-2 variant overexpression increased the amount of mRFP-LC3-I relative to the amount of mRFP-LC3-II in the presence of lysosomal inhibitors, detected by immunoblotting with anti-LC3 antibody, and decreased the ratio of LC3-II/I compared with Beclin-1 alone, consistent with a Bcl-2-dependent reduction in mRFP-LC3-II synthesis and turnover ( Figure 4c ). When HeLa cells were starved of nutrients in earle' balanced salt solution in the absence of the inhibitors, ER-Bcl-2 decreased LC3 II/I significantly (P ¼ 0.002), whereas the decrease with mit-Bcl-2 was not statistically significant (P ¼ 0.08), in keeping with earlier reports using Bcl-2 or Bcl-xL (Maiuri et al., 2007b) . These data show that overexpressed Bcl-2 and Beclin-1 interact functionally in the cells.
Interaction between Beclin-1 and Bcl-2 does not alter apoptosis induced by several death stimuli To examine whether Beclin-1 alters the anti-apoptotic activity of Bcl-2, we transfected HeLa cells with either Figure 2 Beclin-1-GFP bound to mit-Bcl-2 or ER-Bcl-2 is localized to the appropriate membranes. HeLa cells expressing Beclin-1-GFP alone or together with the Bcl-2 variants were fixed and labeled with anti-GFP antibody followed by a secondary antibody conjugated to 5 nm gold particles (bar, 0.5 mm). Note the high proportion of particles concentrated at the ER in the presence of ER-Bcl-2 (inset is ER from another section), at mitochondria in the presence of mit-Bcl-2 and a less specific pattern encompassing several organelles, including nuclear membrane, for wt-Bcl-2.
Beclin-1 or Bcl-2 variants alone or together. After verifying that the amount of Beclin-1 and Bcl-2 variants expressed when transfected singly or together was equivalent (Figure 5a ), cells were exposed to four different pro-apoptotic stimuli chosen because Bcl-2 variants may protect against each differentially depending on their subcellular location (Annis et al., 2004) . Live cells were stained with Hoechst 33342 and propidium iodide to visualize nuclear morphology and distinguish apoptosis from necrosis (primary or secondary) (Figure 5b ). Each stimulus induced mostly apoptotic cell death (TNFa and cycloheximide (CHX), 90%; ultraviolet light (254 nm) UVC or staurosporine (STS) treatments, 40%; thapsigargin and tunicamycin (Tg/ Tm), 20% after 24 h; Figure 5b ), also indicated by the >90% inhibition of cell death by the pan-caspase inhibitor Boc-Asp (Omethyl) fluoromethyl-ketone (BAF) (Supplementary Figure S3) . Further, the relative potency of each stimulus was preserved when apoptosis was measured using biochemical assays such as poly-ADP-ribose polymerase (PARP)-cleavage and caspase-3/7 activity, using DEVD-AMC as substrate (Figures 5c  and d; Supplementary Figure S3 ). These data confirm that apoptotic cell death was triggered by each of the death inducers.
In the absence of Beclin-1, the Bcl-2 variants decreased apoptosis by 40-70%, the potency varying somewhat depending on the type of stimulus and assay. When Beclin-1 was coexpressed with the Bcl-2 variants, protection by Bcl-2 was not altered significantly in response to any of the stimuli (Figures 5b-d) . Overexpression of Beclin-1 alone also had no statistically significant effect on the extent of apoptosis.
Bax activation was also investigated by cotransfecting the cells with mRFP-Bax ( Figure 6 ). In cells treated with Tg/Tm and expressing Beclin-1 alone, fragmentation and condensation of mitochondria was marked by mRFP-Bax punctation at mitochondria and loss of cytoplasmic mRFP-Bax. Nuclear fragmentation was notable. The Bcl-2 variants suppressed mitochondrial fragmentation and Bax punctation, leaving 80-90% of cells with cytoplasmic Bax, quantified in Figure 6b . A similar result was obtained using STS (Figure 6b , cell data not shown). With Beclin-1 alone, mRFP-Bax remained in the cytoplasm, as in control cells (Figures 6a and b) . Thus, Beclin-1 does not disrupt the prevention by Bcl-2 of Bax punctation induced by apoptotic stimuli.
To sensitize the cells to possible modulation of Bcl-2 activity by Beclin-1, the amount of Bcl-2 was reduced relative to that of Beclin-1 so that only partial protection would be achieved. The reduction in Bcl-2 expression relative to Beclin-1 was shown by immunoblotting ( Figure 7a ). To estimate the amount of Beclin-1 relative to Bcl-2 in terms of molar ratios, we calibrated the Bcl-2/Beclin-1 interactions and apoptosis IA Ciechomska et al detection of the primary antibodies to actual antigenconcentration by overexpressing Flag-Beclin-1 together with Flag-Bcl-2, wt-Bcl-2 or mit-Bcl-2. The blot was probed with Flag-Ab (Figure 7b ), thereby allowing us to calculate the ratio of Flag-Beclin-1 to Flag-Bcl-2, then stripped and the bottom portion reprobed with anti-Bcl-2 to compare the relative expression of Flag-Bcl-2 with wt-or mit-Bcl-2 (Figure 7b ). The top portion was reprobed with anti-Beclin-1 to verify results using antiFlag antibody. Using identical amounts of each plasmid for all assays, the titration yielded molar ratios of Beclin-1 to Bcl-2 of 0.28, 0.83, and 1.67, Bcl-2 plasmid being reduced by 3-and 10-fold. In keeping with these ratios, weaker protection against apoptosis induced by TNFa and CHX was found in cells expressing less wt-Bcl-2, measured by PARP cleavage (Figure 7a ) or by counting apoptotic cells (Figure 7c ), but this inhibition was not modified by Beclin-1. To examine whether the interaction between Beclin-1 and wt-Bcl-2 was disrupted during apoptosis, Beclin-1 and wt-Bcl-2 were coimmunoprecipitated from extracts of HeLa cells treated with TNFa and CHX. There was no major change in the amount of Beclin-1/Bcl-2 complex formed after induction of apoptosis, irrespec- Bcl-2/Beclin-1 interactions and apoptosis IA Ciechomska et al tive of whether immune capture was carried out against Flag-Beclin-1 coexpressed with wt-Bcl-2 or against Flagwt-Bcl-2 coexpressed with Beclin-1-GFP (Figure 7d ). These results suggest that the lack of disruption of the anti-apoptotic effect of Bcl-2 by Beclin-1 is not related to the presence of excess free Bcl-2 or to a disruption of the Beclin-1/Bcl-2 interaction after induction of apoptosis.
Genetic ablation of autophagy does not disclose a proapoptotic function of Beclin-1 One possible explanation for the lack of an antagonistic effect of Beclin-1 against Bcl-2 is that an induction of autophagy by Beclin-1 (as shown in Figure 4 ) is supporting survival, thereby compensating for the possible loss of protection by Bcl-2 complexed to Beclin-1. We therefore repeated these experiments using Atg5À/À MEF cells, in which macroautophagy is absent, confirmed by lack of LC3-II formation (Figure 8a ). Similar changes in the subcellular distribution of Beclin-1 were found after overexpression of Bcl-2 variants in Atg5À/À MEF cells as those found in HeLa cells (Figure 8b ). Appropriate localization of mit-Bcl-2 and ER-Bcl-2 to mitochondria and ER was also verified (Supplementary Figure S4) . Hence, the interaction of Beclin-1 with Bcl-2 is independent of autophagic activity. Coimmunoprecipitation experiments further verified the molecular interaction between the two proteins ( Figure 8c ). Despite the lack of autophagy in Atg5À/À MEF cells, the protection against apoptosis induced by different stimuli (STS, Tg/Tm and TNFa/ from at least five independent experiments. Symbols indicate differences between apoptotically-induced cells transfected with control vector, against similarly treated cells transfected with Beclin-1 alone or in combination with the various Bcl-2 variants. ANOVA was followed by Tukey's posthoc test (*Po0.05, **Po0.01). There were no significant differences between results with Beclin-1 alone, control vector or between Beclin-1 alone, Beclin-1 with Bcl-2 except the bar marked # (Po0.05). (c) Immunoblot probed for poly-ADP-ribose polymerase (PARP). Tubulin in the lysates served as loading control (not shown). (d) Caspase-3 activity assessed in HeLa cells treated with the indicated proapoptotic factors by measuring the cleavage of the fluorogenic substrate Ac-DEVD-AMC. Rate was normalized to caspase-3 activity in cells transfected with empty vector. Numbers in bars indicate fold increase in caspase-3 activity relative to that of untreated cells. Beclin-1 alone had no significant effect on basal activity (n ¼ 10) or compared with control vector after induction of apoptosis. Results shown represent mean±s.e.m. from at least three independent experiments. ANOVA was followed by Tukey's posthoc test (*Po0.05, **Po0.01). CHX) when Bcl-2 variants were expressed was not altered by coexpression of Beclin-1. The amount of cell death was estimated by counting Hoechst-and propidium iodide-positive cells and by detection of active caspase-3 by immunoblotting (Figures 8d and e) . We also measured the amount of apoptosis in HeLa cells when autophagy was inhibited by 3-methyladenine (Supplementary Figure S5) . Although 3-methyladenine was toxic and its toxicity synergized with that of STS, as shown earlier in other cell systems (Ravikumar et al., 2006) , nevertheless, the same amount of protection by Bcl-2 variants was found in cells expressing Bcl-2 alone, or Bcl-2 and Beclin-1 (measured by PARP cleavage). These results strengthen the conclusion that Beclin-1 does not prevent Bcl-2 from inhibiting apoptosis irrespective of whether autophagy is active or inactive.
Discussion
The results described here show that binding of Bcl-2 to Beclin-1 does not reduce Bcl-2's anti-apoptotic function irrespective of whether Bcl-2 is bound to ER or Bcl-2/Beclin-1 interactions and apoptosis IA Ciechomska et al mitochondrial membranes, or is not abundantly targeted to one specific organelle. The recruitment of Beclin-1 to Bcl-2 was powerfully shown at the cellular level, in which sequestration of Bcl-2 at organelles led to almost complete colocalization of Beclin-1 to the same cellular sites. Likewise, binding of Beclin-1-GFP to organelle-targeted Bcl-2 variants was verified by coimmunoprecipitation with either protein as 'bait'. Protection by Bcl-2 against apoptosis was obtained against several types of apoptotic inducers irrespective of whether the signals originated at the ER (using Tg/Tm), at death receptors (TNFa, through tBidmediated apoptosis) or through less selective signals that are not dominated by ER dependence (UVC and Figure 7 Beclin-1 does not augment apoptosis when Bcl-2 is expressed sub-optimally, nor does apoptosis disrupt Beclin-1/Bcl-2 interaction. HeLa cells were transfected with Beclin-1 and wt-Bcl-2 at plasmid ratios that give rise to molar ratios of Beclin-1/Bcl-2 protein of 0.28, 0.83 and 1.67. The amount of Beclin-1 was increased from 0.4 to 0.7 mg as the amount of Bcl-2 plasmid was reduced in the latter two conditions to keep the overall amount of plasmid constant. The amount of Bcl-2 plasmid was reduced by 3-or 10-fold. Cells were untreated (UNT) or induced to undergo apoptosis with TNFa (100 ng/ml)/CHX (20 mM) for 5 h. (a) Analysis by immunoblotting for PARP cleavage, Beclin-1 or Bcl-2 to show the dose-dependent reduction in Bcl-2 compared with Beclin-1. Tubulin was used as a loading control. (b) Cells were cotransfected with Flag-Beclin-1, Flag-Bcl-2 or wt-Bcl-2 or mit-Bcl-2. Extracts were probed on a single blot with anti-Flag, then stripped and reprobed for Beclin-1 or Bcl-2 expression. A comparison of the intensity of the Flag-Bcl-2 with Flag-Beclin-1 or the intensity of the Bcl-2 variants on the blot probed with ani-Bcl-2, enabled an estimate of the molar ratios of Beclin-1 to Bcl-2 (ratios of Beclin-1 to Bcl-2 shown in panel c). (c) Apoptosis of cohort samples was measured by scoring the percentage of Hoechst-positive nuclei that were condensed or fragmented. Necrosis was scored using propidium iodide (PI). Results are mean ± s.e.m. of six (0.28 Bec/Bcl-2), four (0.83 Bec/Bcl-2) and five (1.67 Bec/Bcl-2) independent repeats. ***Po0.001, **Po0.01, *Po0.05. (d) Flag-Beclin-1 and Bcl-2 or Flag-Bcl-2 and Beclin-GFP were cotransfected (0.83 Bec/Bcl-2 ratio). Extracts were prepared after 48 h from untreated (UNT) HeLa cells or from cohort cells treated with TNFa (100 ng/ml)/CHX (20 mM) for 5 h. Proteins were immunoprecipitated on Flag-sepharose beads, eluted by boiling and blots were probed for Beclin-1 and Bcl-2. Note that all the lanes were on same blot.
Bcl-2/Beclin-1 interactions and apoptosis IA Ciechomska et al STS) (Annis et al., 2004) . Even when sub-maximal amounts of Bcl-2-mediated protection were established to leave room for extending the extent of apoptosis, Beclin-1 overexpression failed to modulate apoptosis. Moreover, no change in the protection against apoptosis by Bcl-2 during binding of Beclin-1 was observed in Atg5À/À MEFs, excluding the possibility that a Beclin-1-mediated increase in autophagy was generating a prosurvival signal that compensates for a putative loss of anti-apoptotic function of Bcl-2 complexed to Beclin-1. Hence, Beclin-1 is an atypical BH3-domain-containing protein in that its expression in cells that depend for survival on overexpressed Bcl-2 is not sufficient to induce apoptosis. This result contrasts with overexpression of Puma, for example, which led to rapid apoptosis of untreated HeLa cells , showing that the cells are 'primed' and competent to die (Certo et al., 2006) . Why Beclin-1 is different from other BH3-only proteins is still unclear. The sufficiency of the Beclin-1 BH3-domain alone to induce apoptosis through its binding to Bcl-xL (Maiuri et al., 2007a, b) has raised the suggestion that there are counteracting regulatory sequences that may normally prevent the BH3 motif in Beclin-1 from activating apoptosis when present within the full-length protein, as discussed by Levine et al. (2008) . Different binding interactions for the BH3-domain of Beclin-1 bound to Bcl-xL compared with other BH3-domains were also reported (Feng et al., 2007; Oberstein et al., 2007) . Moreover, Beclin-1 is bound to many other proteins in addition to Bcl-2 family members (Vps34 (Furuya et al., 2005) , UVRAG (Liang et al., 2006; Takahashi et al., 2007) , Bif1 (Takahashi et al., 2007) Ambra (Fimia et al., 2007) ), which may further obscure the function of the BH3-domain. It is interesting to note that UVRAG was recently reported to modulate the stoichiometry of Beclin-1 binding to Bcl-2/xL (Noble et al., 2008; Samara et al., 2008) , but the impact on apoptosis is not known. Our studies with Vps34 did not reveal a difference in the amount of Vps34 that coimmunoprecipitates or colocalizes with Beclin-1 in the absence or presence of Bcl-2 (CL Tan and I Ciechomska, unpublished data), in keeping with the data of Maiuri et al. (2007a) , but not that of Pattingre et al. (2005) . The impact of the other interactions remains to be tested.
We found that all three Bcl-2 variants protected against apoptosis in HeLa cells irrespective of Beclin-1, the efficacy varying depending on type of stimulus, as noted earlier (Annis et al., 2004) . All the variants inhibited Beclin-1-induced autophagy in the presence of the lysosomal inhibitors pepstatinA and E64d, but under conditions of amino acid starvation, ER-Bcl-2 was most effective, as shown earlier Maiuri et al., 2007b) . Our findings support the idea proposed by Maiuri et al. (2007b) that different pools of anti-apoptotic Bcl-2 proteins that inhibit apoptosis or autophagy differentially are more relevant under conditions of starvation than under nutrientreplete, apoptotic conditions. Also, the affinity of Beclin-1 to the various anti-apoptotic Bcl-2 family members is not equivalent (Erlich et al., 2007) , therefore it is possible that the apoptotic outcome will be different when other Bcl-2 anti-apoptotic members are expressed, or used in other cell types.
The relationship between autophagy, non-apoptotic ('autophagic') and apoptotic cell death, and the roles of Beclin-1 and anti-apoptotic Bcl-2 proteins in these processes are still incomplete. Initially, it was suggested that Bcl-2 and Bcl-xL enhance autophagy induced by an apoptotic insult (in Bax/Bak double-knockout cells that cannot undergo apoptosis) by upregulation of Beclin-1, and thereby mediate autophagy-dependent death (Shimizu et al., 2004; Swerdlow et al., 2008) . More recently, different outcomes were observed: autophagy induction by glucocorticoid in T cells was dependent on the expression of Bcl-2 without detectable Beclin-1/Bcl-2 interactions, but with ensuing survival (Swerdlow et al., 2008) , whereas in MCF7 cells with endogenous Beclin-1, knockdown of Bcl-2 increased autophagy and cell death (Akar et al., 2008) . Further studies that take all the participating proteins into account are needed to establish whether these different mechanisms can be reconciled.
What might be the consequences of the fact that Beclin-1 binding to Bcl-2 may reduce the extent of autophagy, but not the protection, against apoptosis? ATG6/beclin-1 is frequently inactivated at one locus in human cancers and, conversely, Beclin-1 overexpression suppresses the tumorigenicity of human cancer lines (Aita et al., 1999; Liang et al., 1999; Qu et al., 2003; Yue et al., 2003) . Tumors also develop spontaneously in mice containing one copy of beclin-1 (Yue et al., 2003) . The detailed mechanisms by which Beclin-1 and the autophagic machinery contribute to tumor suppression are not clear (Jin and White, 2008; Mizushima et al., 2008) . Our study suggests that the putative pro-apoptotic function of Beclin-1 is very weak to negligible, leading us to reject the possibility that suppression of tumor function by Beclin-1 in mammals is because of its negative effects on Bcl-2. A study of thymocytes from a transgenic Beclin-1-GFP mouse suggests that thymocytes expressing relatively high amounts of Beclin-1-GFP compared with endogenous protein seem increasingly sensitive to glucocorticoid-induced apoptosis in vitro. Whether this occurs through binding to Bcl-2 or other Bcl-2 family members was not addressed. Whether Beclin-1 can be manipulated to enhance the death of cancer cells expressing high amounts of Bcl-2 needs to be tested. It will be equally important to assess whether Beclin-1 disturbs the pro-survival effect of Bcl-2 in the nervous system, given that some classes of neurons depend on Bcl-2 for long-term survival (Michaelidis et al., 1996) .
In summary, our data suggest that expression of high amounts of Beclin-1 does not disturb the protective effect of Bcl-2 against apoptosis induced by several types of apoptosis inducers irrespective of the location of Bcl-2 in the cell. It will be important to determine whether the function of every anti-apoptotic Bcl-2 family member is similarly unaffected by excess expression of Beclin-1.
Materials and methods

Cell lines and treatments
Cell lines (HeLa, SV40 large T-immortalized ATG5 þ / þ and ATG5À/À MEFs, a kind gift from Dr Noboru Mizushima, Tokyo Medical and Dental University, Tokyo, Japan (Kuma et al., 2004) were grown in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin. Cell death was induced by STS (1-0.25 mM, Sigma-Aldrich, St Louis, MO, USA) for 16-24 h, thapsigargin and tunicamycin (Tg, 2 mM, Tm, 10 mg/ml, Sigma-Aldrich) for 16-24 h, TNFa (100 ng/ml, Biosource Invitrogen, Paisley, Scotland) and CHX (20 mM, Sigma-Aldrich) for 5-7 h, or irradiated in phosphatebuffered solution with UVC (300 J/m 2 ) using a Stratalinker UV crosslinker (Stratagene, Agilent Technologies, Santa Clara, CA, USA), then returned to growth medium and analysed after 5 h. Starvation in earle' balanced salt solution (Invitrogen, Paisley, Scotland) was carried out after four washes in phosphate-buffered solution. Pepstatin A (Sigma-Aldrich) and E64d (Calbiochem Merck, Nottingham, UK) were present at 10 mg/ml.
Transfection
Transient transfection was carried out with Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instructions. Cells were transfected with Flag-hBeclin-1, FlaghBeclin-1(DBcl-2BD) or hBeclin-1(DBcl-2BD)-GFP (generously provided by Beth Levine, University of Texas Southwestern Medical Center at Dallas) or mouse Beclin-1-GFP (generously provided by Zhenyu Yue, Mount Sinai School of Medicine, New York) fusion constructs alone or in combination with plasmids encoding wild-type Bcl-2 (wt-Bcl-2) or Bcl-2 variants targeted at their C-termini to the mitochondrial outer membrane (mit-Bcl-2) or the ER membrane (ER-Bcl-2) (Hacki et al., 2000; Kaufmann et al., 2003) (generously provided by Christoph Borner, IMMCR, Albert-Ludwigs-Universita¨t, Freiburg). For immunocytochemistry, immunoprecipitation, immunoblot and caspase assays, cells were cotransfected so that they expressed 0.8-or 1.7-fold molar ratios of Beclin-1 to Bcl-2. When combined with mRFP-LC3 or mRFP-Bax plasmids, cells were transfected at 0.25:1 ratio to the Beclin-1 plasmid. To inhibit apoptosis or caspase activity, cells were treated with 50 mM Boc-Asp (O-methyl)-CH2F (BAF).
Immunoblotting and immunoprecipitation
For blotting, cells were lysed in 1% NP-40 buffer (Ciechomska et al., 2008) supplemented with complete protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN, USA). About 15-30 mg of protein was loaded on 10-15% SDSpolyacrylamide gel (SDS-PAGE) and transferred to a nitrocellulose membrane by electroblotting. Membrane was blocked in 5% non-fat milk in TBS-Tween 20 (0.1%) and incubated with primary antibodies: anti-Beclin-1 (Cell Signaling, NEB, Hitchin, UK or Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-Bcl-2 (Santa Cruz Biotechnology), anti-active caspase-3 (Cell Signaling), anti-PARP (generous gift from Dr S Aoufouchi, Faculte´de Me´decine Necker-Enfants Malades, Universite´Paris V, France), anti-a-tubulin (Sigma) and anti-LC3 (generous gift from Dr E Kominami, Juntendo University School of Medicine, Tokyo, Japan). Blots were developed by chemiluminescence using Amersham ECL reagents (GE Healthcare, Little Chlafont, UK). For immunoprecipitation, cell extracts were prepared in ice-cold 500 ml modified RIPA buffer (50 mM Tris-HCl, pH 7.4; 1% NP-40; 1% sodium deoxycholate; 0.1% SDS, 150 mM NaCl; 2 mM EDTA; 25 mM sodium fluoride, 1 mM each of PMSF, sodium orthovandate and sodium fluoride; 1 mg/ml each of aprotinin, leupeptin and pepstatin). A 45 ml aliquot was removed for input determination, 30 ml of anti-Flag conjugated to sepharose beads (SigmaAldrich) was added to the remaining extract and immune complexes were pelleted after overnight incubation at 4 1C. After removal of 45 ml to determine output, beads were washed five times with modified RIPA buffer, proteins were eluted with SDS-loading buffer and analysed by SDS-PAGE and immunoblotting. Band density was quantified using ImageJ software.
Caspase-3 activity assay Caspase-3 activity was measured in a cytosolic extract using the fluorogenic substrate Ac-DEVD-AMC (N-acetyl-Asp-GluVal-Asp-7-amino-4-methylcoumarin) (Biomol, Exeter, UK), as described earlier (Ciechomska et al., 2008) . Fluorescence was read at 10 min intervals for up to 120 min at 37 1C and the rate of activity was calculated from the linear portion of the curve.
Immunofluorescence analysis Cells grown on coverslips were fixed with 3% paraformaldehyde in phosphate-buffered solution at room temperature for 15 min and post-fixed for 10 min in 100% methanol at À20 1C. Primary antibodies (anti-Bcl-2 (Santa Cruz Biotechnology), anti-KDEL for ER detection (MAC256, a generous gift from GW Butcher, The Babraham Institute, Cambridge)) were diluted in 1% bovine serum albumin containing 0.1% TritonX-100 and incubated with cells at 4 1C overnight. Antibodies were visualized with anti-rabbit Cy3-or Alexa-647-conjugated secondary antibodies (Molecular Probes, Invitrogen, Paisley, Scotland). Cells were counterstained with 1 mg/ml Hoechst 33342 and mounted in Fluoromount-G (SouthernBiotech, Birmingham, AL, USA). To visualize mitochondria, cells were stained before fixation with mitotracker orange (100 nM, Molecular Probes) for 15 min. Cells were analysed by confocal microscopy (Olympus IX70, Olympus UK, Southall, Middlesex, UK) connected to an UltraVIEW LCI confocal imaging system (Perkin-Elmer LAS, Seer Green, Bucks, UK). Digital images were acquired and analysed using UltraVIEW software. Intensity of cytoplasmic mRFP-LC3 was determined using ImageJ software. 
Quantification of apoptosis
Unfixed cells were costained with 5 mg/ml each propidium iodide (red) and Hoechst 33342 (blue) to visualize nuclear morphology and distinguish between necrosis and apoptosis. Uniformly bluestained nuclei were scored as healthy, viable cells, whereas condensed or fragmented nuclei that stained blue were counted as apoptotic. All red-stained condensed or fragmented nuclei were scored as necrotic, even when fragmentation of the nucleus suggested that necrosis was secondary to apoptosis. Cell death was calculated from at least four randomly selected fields, containing at least 200 cells for each condition.
Immunoelectron microscopy HeLa cells were fixed for 0.5 h in 3% paraformaldehyde in phosphate-buffered solution, followed by 30 min in 3% formaldehyde and 0.05% glutaraldehyde in PIPES buffer pH 7.4 containing 2 mM CaCl 2 . Samples were prepared by freeze substitution as described earlier (Skepper, 2000) . Thin sections of HeLa cells expressing Beclin-1-GFP in the absence or presence of wt-Bcl-2, mit-Bcl-2 or ER-Bcl-2 were incubated with polyclonal antibody anti-GFP followed by incubation with gold-conjugated goat antirabbit secondary antibody (British BioCell International, Cardiff, Wales). After immunolabeling, sections were stained with 2% uranyl acetate and lead citrate and viewed in a Philips CM100 electron microscope (Eindhoven, Holland). Grain density per unit length was measured using ImageJ software.
Statistical analysis
Statistical analyses were carried out using Microsoft Excel or Statistica (ver. 7.1 StatSoft Inc., Tulas, OK, USA) software. For comparisons of means, one-way ANOVA was followed by Newman-Keuls or Tukey's post-hoc tests, or one sample t-test.
